Literature DB >> 10495432

Over-expression of cyclin D1 induces glioma invasion by increasing matrix metalloproteinase activity and cell motility.

T Arato-Ohshima1, H Sawa.   

Abstract

In order to define the role of cyclin D1 in the progression of malignant glioma, cells over-expressing cyclin D1 were constructed (a-1 cells). They exhibited significantly increased invasiveness as compared with mock-transfected cells. Since cellular invasion is thought to depend on extracellular-matrix degradation, we determined whether cyclin-D1 expression modifies the activity of matrix metalloproteinases (MMPs). Increased gelatinolytic activity of latent type MMP-2 (proMMP-2) and active MMP-2 was observed in a-1 cells. Moreover, cyclin-D1 expression was associated with increased activation of proMMP-9 through MMP-3. Wound assays showed an increase of cell motility in a-1 cells. Cyclin-D1 expression was found to be associated with up-regulation of Rac1, which modulates the formation of ruffling membranes and cell motility. Our results show that cyclin D1 may modulate invasive ability by increasing MMP activity and cell motility, and suggests a novel function of cyclin D1 in the progression of malignant gliomas. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10495432     DOI: 10.1002/(sici)1097-0215(19991029)83:3<387::aid-ijc15>3.0.co;2-o

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

1.  Cholera toxin induces malignant glioma cell differentiation via the PKA/CREB pathway.

Authors:  Yan Li; Wei Yin; Xia Wang; Wenbo Zhu; Yijun Huang; Guangmei Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-06       Impact factor: 11.205

2.  MicroRNA-195 inhibits proliferation of cervical cancer cells by targeting cyclin D1a.

Authors:  Ning Wang; Heng Wei; Duo Yin; Yanming Lu; Yao Zhang; Qiao Zhang; Xiaoxin Ma; Shulan Zhang
Journal:  Tumour Biol       Date:  2015-10-28

3.  LEF1 regulates glioblastoma cell proliferation, migration, invasion, and cancer stem-like cell self-renewal.

Authors:  Xingchun Gao; Yajing Mi; Yue Ma; Weilin Jin
Journal:  Tumour Biol       Date:  2014-08-16

Review 4.  Proteases and the biology of glioma invasion.

Authors:  Devin K Binder; Mitchel S Berger
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

5.  Withania somnifera Suppresses Tumor Growth of Intracranial Allograft of Glioma Cells.

Authors:  Hardeep Kataria; Sushil Kumar; Harshita Chaudhary; Gurcharan Kaur
Journal:  Mol Neurobiol       Date:  2015-07-26       Impact factor: 5.590

6.  Expression studies in gliomas and glial cells do not support a tumor suppressor role for LGI1.

Authors:  Tiziana Piepoli; Cemile Jakupoglu; Wenli Gu; Elena Lualdi; Blanca Suarez-Merino; Pietro L Poliani; Maria Grazia Cattaneo; Barbara Ortino; Dorota Goplen; Jian Wang; Rosa Mola; Francesca Inverardi; Carolina Frassoni; Rolf Bjerkvig; Ortrud Steinlein; Lucia M Vicentini; Oliver Brüstle; Gaetano Finocchiaro
Journal:  Neuro Oncol       Date:  2006-03-02       Impact factor: 12.300

7.  An acidic environment changes cyclin D1 localization and alters colony forming ability in gliomas.

Authors:  Joachim B Schnier; Kayoko Nishi; William R Harley; Fredric A Gorin
Journal:  J Neurooncol       Date:  2008-04-11       Impact factor: 4.130

8.  Upregulation of KIF11 in TP53 Mutant Glioma Promotes Tumor Stemness and Drug Resistance.

Authors:  Bin Liu; Gang Zhang; Shukun Cui; Guoliang Du
Journal:  Cell Mol Neurobiol       Date:  2021-01-25       Impact factor: 5.046

9.  Intratumoral delivery of shRNA targeting cyclin D1 attenuates pancreatic cancer growth.

Authors:  S J Deharvengt; J R Gunn; S B Pickett; M Korc
Journal:  Cancer Gene Ther       Date:  2009-10-23       Impact factor: 5.987

10.  MicroRNA-195 inhibits the proliferation of human glioma cells by directly targeting cyclin D1 and cyclin E1.

Authors:  Wang Hui; Lu Yuntao; Luo Lun; Li WenSheng; Liang ChaoFeng; He HaiYong; Ba Yueyang
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.